PCM
CLVS

Palisade Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Palisade Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,000
Closed -$102K – 418
2020
Q1 		$102K Buy
16,000
+2,000
+14% +$16K ﹤0.01% 413
2019
Q4 		$146K Sell
14,000
-4,100
-23% -$29.8K ﹤0.01% 407
2019
Q3 		$71K Buy
+18,100
New +$146K ﹤0.01% 420
2015
Q4 		– Sell
-70,937
Closed -$6.52M – 544
2015
Q3 		$6.52M Buy
70,937
+65,437
+1,190% +$5.66M 0.19% 189
2015
Q2 		$483K Buy
+5,500
New +$471K 0.01% 475

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return